Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study
Background: HIV and hepatitis B virus (HBV) coinfection has been associated with a higher risk of morbidity and mortality. HBV-active antiretroviral regimens have significantly improved the outcomes for coinfected people. Although bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is safe...
Saved in:
| Main Authors: | Helena Kwakwa, Jacqueline Bran, Julia Ruff, Salma Sharaf, Hyunuk Seung, Sunny Choe, Joel V. Chua |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/17/4/510 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Aleksandra Berkan-Kawińska, et al.
Published: (2024-07-01) -
Successful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide
by: Coskun Ekemen, et al.
Published: (2025-07-01) -
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance– a phase IV randomised, open-label study (PIBIK study)
by: Collins Iwuji, et al.
Published: (2025-02-01) -
Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study
by: Ping‐Feng Wu, et al.
Published: (2024-12-01) -
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-12-01)